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Introduction
Psychiatric comorbidities are relatively common in patients with epilepsy, with a higher prevalence than that observed in the general population (Kanner, 2016a; Verrotti et al., 2014) .
Depression and anxiety are the most common psychiatric comorbidities in patients with epilepsy and are strong predictors of suicide, premature death, poor quality of life, and intolerance to antiepileptic drugs (AEDs) (Kanner, 2016a) . Symptoms of depression may be present in 20-60% of patients with epilepsy, and the prevalence of anxiety is estimated to be 15-20% (Verrotti et al., 2014) . Psychiatric conditions, including depression, may precede the onset of epilepsy (Mula, 2017a) . Furthermore, a history of depression before the onset of seizures has been linked to an increased risk of treatment-resistant epilepsy (Hitiris et al., 2007; Petrovski et al., 2010) . Psychiatric comorbidities have a more severe impact on quality of life than the actual seizures in patients with treatment-resistant focal epilepsy (Kanner, 2016a) , and psychiatric comorbidities have been associated with a high use of healthcare resources (Cramer et al., 2004; Patel et al., 2017) .
Psychiatric comorbidities and epilepsy have a complex relationship which has a direct bearing on the management of both comorbidities and seizures (Kanner, 2016a) . Some AEDs may cause psychiatric side effects and exacerbate existing psychiatric disorders (Besag, 2004; Schmitz, 2006) . The presence of psychiatric comorbidities should therefore be considered when selecting the most appropriate antiepileptic treatment (Kanner, 2016a; Verrotti et al., 2014) . The potential risk of seizures should also be taken into account when selecting the most appropriate drugs to treat psychiatric comorbidities in patients with epilepsy, as it has been suggested that some antidepressants (e.g., tricyclic antidepressants) may induce seizures (Kanner, 2016a; Montgomery, 2005; Verrotti et al., 2014) .
Lacosamide is a third-generation AED, which is indicated for the treatment of focal (partialonset) seizures in patients 4 years of age and older in the European Union (EU) and United States (UCB Inc, 2019; UCB Pharma SA, 2018) . Adjunctive lacosamide was associated with a low incidence of psychiatric treatment-emergent adverse events (TEAEs) in a pooled analysis of double-blind, placebo-controlled trials and in a long-term, open-label, noninterventional safety study in clinical practice (Biton et al., 2015; Steinhoff et al., 2016) . Data on the tolerability and efficacy of lacosamide in patients with concomitant psychiatric conditions are limited. In a large-scale double-blind trial (SP0993), lacosamide was noninferior to carbamazepine controlled-release (carbamazepine-CR) as initial monotherapy in patients with J o u r n a l P r e -p r o o f newly diagnosed epilepsy, and was generally well tolerated (Baulac et al., 2017) . This exploratory post hoc analysis of the SP0993 trial data assessed the tolerability and efficacy of lacosamide and carbamazepine-CR monotherapy in patients with concomitant psychiatric conditions.
Methods

Overall trial design and patients
SP0993 (NCT01243177) was a Phase III, multicenter, double-blind, randomized, noninferiority trial conducted at 185 sites in 29 countries in Europe, North America, and the Asia Pacific (Baulac et al., 2017) . This trial evaluated the efficacy and tolerability of lacosamide versus carbamazepine-CR monotherapy in patients with newly diagnosed epilepsy (Baulac et al., 2017) . The trial was conducted in accordance with Good Clinical Practice, the Declaration of Helsinki, and local laws. A national, regional, or independent ethics committee or institutional review board reviewed the trial protocol, amendments, and patient informed consent.
The trial methodology has been published in detail previously (Baulac et al., 2017) and is summarized briefly here. Patients were eligible for this trial if they were at least 16 years of age with newly or recently diagnosed epilepsy with unprovoked focal (partial-onset) seizures.
Patients with generalized tonic-clonic seizures (GTCS) without clear focal origin were also eligible, provided that they did not have a history of, or clinical or electroencephalogram (EEG) findings suggestive of genetic generalized epilepsy. Patients were required to have at least two unprovoked seizures separated by at least 48 h in the 12 months before screening, of which at least one had occurred in the 3 months before screening. Patients were also required to have had an EEG and a brain computed tomography scan or magnetic resonance imaging examination within the past 12 months before randomization.
Patients were excluded from this trial if they had a history or presence of seizure clusters or status epilepticus, seizure types other than focal or GTCS, a diagnosis of nonepileptic seizures, conversion disorders, or other nonepileptic ictal events that could have been confused with seizures. Patients with atrioventricular block or any other clinically relevant electrocardiographic abnormalities were excluded. In addition, patients were excluded if they had a history of suicide attempt or current suicidal ideation, a history of alcohol or drug abuse within the previous 2 years before screening, or any medical or psychiatric condition which, in the opinion of the investigator, could have jeopardized their health or compromised their ability to participate in the trial.
J o u r n a l P r e -p r o o f
Patients of Asian ancestry who tested positive for the HLA-B*1502 or HLA-A*3101 allele were excluded. Other exclusion criteria were previous treatment with lacosamide or carbamazepine-CR and treatment with any AED in the 6 months before screening. Patients taking acute or subacute seizure treatment were only included if the treatment had lasted for 2 weeks or less and had ended at least 3 days before randomization. The use of benzodiazepines as a rescue therapy was permitted if taken at a maximum frequency of once weekly. Drugs or products (e.g., grapefruit) that are known to increase plasma levels of carbamazepine, or its active metabolite carbamazepine-10,11-epoxide, were not allowed.
Drugs known to decrease carbamazepine plasma levels were also excluded. The use of monoamine oxidase inhibitors was not permitted within 14 days of trial entry. Antidepressant use (with the exception of amitriptyline, fluoxetine, and mianserin) and/or neuroleptic use were allowed except for those that were known to interact with the trial medication. Women of childbearing age had to use effective methods of contraception.
Patients were randomized 1:1 to lacosamide or carbamazepine-CR stratified by the number of seizures in the 3 months before screening (≥2 or <2 seizures). From starting doses of 100 mg/day lacosamide or 200 mg/day carbamazepine-CR, patients were up-titrated to the first target dose level (200 mg/day lacosamide; 400 mg/day carbamazepine-CR) over 2 weeks (Supplemental Figure) . After stabilization for 1 week, patients entered a 6-month Evaluation period. If a seizure occurred during the 6-month Evaluation period, the dose was titrated to the next target dose level (400 or 600 mg/day lacosamide; 800 or 1200 mg/day carbamazepine-CR) over 2 weeks with a 1-week stabilization period, and the 6-month Evaluation period began again. Patients who experienced a seizure at the third target dose were withdrawn from the trial. Upon completion of the 6-month Evaluation period, patients who remained seizure free continued to a 6-month Maintenance period on the same dose. During the Evaluation or Maintenance period, patients who escalated to the second or third target dose could undergo one dose reduction (100 mg/day lacosamide or 200 mg/day carbamazepine-CR) if they were unable to tolerate the increased dose. These patients could not be returned to the higher target dose or have further up-titration in case a new seizure occurred. Patients who had a seizure during the Maintenance period were withdrawn from this trial. Patients were required to keep a daily diary recording their seizure activity and all efficacy assessments were based on diary data.
Analyses of patients with concomitant psychiatric conditions
These exploratory post hoc subgroup analyses included all patients who reported an ongoing concomitant psychiatric condition (Medical Dictionary for Regulatory Activities [MedDRA] System Organ Class Version 16.1) at the Screening Visit. The safety set (SS) and the full J o u r n a l P r e -p r o o f analysis set (FAS) were defined as all randomized patients who took at least one dose of trial medication, and included the same patients.
Tolerability outcomes were the incidences of TEAEs, psychiatric TEAEs, serious TEAEs, and discontinuations due to TEAEs during the Treatment period (Dose-finding, Evaluation, and Maintenance period combined), and Kaplan-Meier estimated time to discontinuation due to adverse events during the 12 months of treatment since the date of first dose of trial medication. The estimated proportions of patients who remained seizure free for 6 and 12 months after stabilization at the last assessed dose level were analyzed using the Kaplan-Meier method. In the Kaplan-Meier analyses, the results were adjusted for the number of seizures (≤2 or >2) in the 3 months before screening. Patients who discontinued because of nonseizure-related reasons were considered as being seizure free and censored at the last dose of trial medication during the Treatment period. The proportion of patients who completed 6 and 12 months of treatment at the last evaluated dose level and were seizure free for 6 and 12 months, respectively, was also assessed. All other outcomes were summarized descriptively. A numerically higher proportion of patients on lacosamide (32 [50.0%]) than on carbamazepine-CR (22 [35.5%]) completed the trial (Fig. 1) . The most common reasons for trial drug discontinuation were lack of efficacy (18.8%) and adverse event (10.9%) in patients on lacosamide, and adverse event (24.2%), consent withdrawn (14.5%), and lack of efficacy (11.3%) on carbamazepine-CR.
Results
Patient disposition
Baseline demographics
Baseline demographics were comparable between the lacosamide and carbamazepine-CR treatment groups (Table 1) . The most common psychiatric conditions in all patients were depression (38.1%), insomnia (27.8%), and anxiety (26.2%) (Table 1) . Depression was slightly more common among patients randomized to lacosamide, whereas anxiety was slightly more common in the carbamazepine-CR group. Of the 35 patients who reported insomnia, 16 J o u r n a l P r e -p r o o f patients (six in the lacosamide and 10 in the carbamazepine-CR group) also had other psychiatric disorders (mainly anxiety and/or depression), and 19 (15.1%) patients included in this analysis reported insomnia only. Of the seven patients who reported sleep disorder, two patients (one in the lacosamide and one in the carbamazepine-CR group) also had other psychiatric disorders, and five patients (4.0%) reported sleep disorder only. A higher proportion of patients on lacosamide than carbamazepine-CR were on antidepressants. 110 (87.3%) patients had at least one nonpsychiatric condition (median 4.0), most commonly hypertension (34.9%), hypercholesterolemia (19.0%), headache (13.5%), and 13.5% reported postmenopause (Table 1) .
Table 1
Baseline demographics and epilepsy characteristics of patients with concomitant psychiatric conditions a (FAS/SS). 
KM-estimated time to discontinuation due to TEAEs
J o u r n a l P r e -p r o o f
Kaplan-Meier estimates for time to discontinuation due to TEAEs suggested that lacosamide was less frequently associated with TEAEs leading to discontinuation than carbamazepine-CR ( Fig. 2) . This difference was apparent by day 60, with Kaplan-Meier estimates for the proportion of patients remaining on treatment of 93.5% with lacosamide and 88.4% with carbamazepine-CR. After 12 months (364 days), the Kaplan-Meier estimates were 88.2% on lacosamide and 72.1% on carbamazepine-CR.
Seizure freedom (6 and 12 months) at last evaluated dose
The stratified Kaplan-Meier estimates for the proportion of patients remaining seizure free for 6 and 12 months at the last evaluated dose level were similar with lacosamide and carbamazepine-CR (6 months: 81.0% and 75.6%; 12 months: 62.5% and 66.6%) (Fig. 3A) .
A numerically higher proportion of patients on lacosamide than carbamazepine-CR completed 6 (lacosamide: 43 [67.2%]; carbamazepine-CR: 28 [45.2%]) and 12 months of treatment without a seizure (lacosamide: 32 [50.0%]; carbamazepine-CR: 23 [37.1%]) at the last evaluated dose (Fig. 3B ).
Discussion
Psychiatric comorbidities are present in approximately 30% of patients with epilepsy (Kanner, 2016b; Karouni et al., 2010) , and have been associated with intolerance to AEDs and an increased risk of treatment-resistant epilepsy (Chen et al., 2017; Chen et al., 2018; Hitiris et al., 2007; Petrovski et al., 2010) . As some AEDs may cause psychiatric side effects and exacerbate existing psychiatric disorders (Besag, 2004; Schmitz, 2006) , it is important to evaluate the tolerability and efficacy of individual AEDs in patients with epilepsy and concomitant psychiatric conditions. In this exploratory post hoc subgroup analysis of data from a randomized double-blind trial, the most common concomitant psychiatric conditions were depression (38%), insomnia (28%), and anxiety (26%), consistent with literature reporting depression and anxiety as the most common psychiatric comorbidities in patients with epilepsy (Kanner, 2016a; Ottman et al., 2011) . This exploratory post hoc analysis suggested that lacosamide monotherapy was generally well tolerated in patients with newly diagnosed epilepsy and concomitant psychiatric conditions.
In this subgroup of patients with concomitant psychiatric conditions, numerically lower overall incidences of TEAEs, drug-related TEAEs, and discontinuations due to TEAEs were observed in patients on lacosamide (81.3%, 45.3%, 10.9%, respectively) than in those on carbamazepine-CR (90.3%, 61.3%, 24.2%). These data were supported by a Kaplan-Meier analysis of time to discontinuation due to TEAEs, which suggested that in patients with concomitant psychiatric conditions, carbamazepine-CR was more frequently associated with J o u r n a l P r e -p r o o f intolerable adverse events than lacosamide. The most common TEAEs in lacosamide-treated patients were dizziness, headache, and nasopharyngitis, in line with those observed in the overall trial population (Baulac et al., 2017) and in previous trials of lacosamide (adjunctive therapy, conversion to monotherapy) in patients with focal seizures (Ben-Menachem et al., 2007; Chung et al., 2010; Halász et al., 2009; Wechsler et al., 2014) .
In both treatment subgroups analyzed, the incidences of TEAEs were numerically higher in patients with psychiatric conditions than in the overall trial population (lacosamide: 81.3% vs 74%; carbamazepine-CR: 90.3% vs 75%) (Baulac et al., 2017) . A similar trend was seen for drug-related TEAEs (lacosamide 45.3% vs 37%; carbamazepine-CR 61.3% vs 46%), and for discontinuations due to TEAEs in carbamazepine-CR-treated patients (24.2% vs 16%) (Baulac et al., 2017) . However, in lacosamide-treated patients, the incidence of discontinuations due to TEAEs was similar in the subgroup of patients with concomitant psychiatric conditions and the overall trial population (10.9% vs 11%) (Baulac et al., 2017) .
The lower incidence of TEAEs with lacosamide than carbamazepine-CR in patients with psychiatric conditions may at least partly be influenced by the fact that a lower proportion of patients on lacosamide than carbamazepine-CR (14.1% vs 19.4%) required a dose escalation to the highest permitted dose level. Furthermore, a higher proportion of patients with psychiatric conditions on carbamazepine-CR (59.7%) than lacosamide (46.9%) had four or more nonpsychiatric comorbid conditions at screening, indicating a more comorbid patient population. Another post hoc analysis of data from the same trial suggested that the incidence of TEAEs, drug-related TEAEs, and discontinuations due to TEAEs increased with a higher number of comorbid conditions. These increases were more pronounced in patients on carbamazepine-CR than on lacosamide (Ryan et al., 2017) .
AEDs can have positive and negative effects on mood and behavior (Kanner, 2016a; Piedad et al., 2012; Schmitz, 2006) . Some AEDs have antidepressant (lamotrigine) or anxiolytic (pregabalin, gabapentin) properties (Kanner, 2016a) , and carbamazepine and valproate are known to have mood-stabilizing effects (Perucca and Mula, 2013) . Psychiatric TEAEs such as depression, anxiety, and psychosis can occur with any AED, but are more likely to occur with high doses of AEDs, in patients with a history of psychiatric disorders, and with AEDs with known psychotropic properties (e.g., topiramate, zonisamide, levetiracetam) (Kanner, 2016a) .
Data have suggested that low starting doses and slow titration schedules may reduce the possibility of psychiatric TEAEs (Mula, 2017b) . A retrospective study found that patients taking sodium channel blockers were less likely to develop intolerable psychiatric side effects compared with those taking AEDs with other mechanisms of action (Stephen et al., 2017) .
In this particular subpopulation of patients with concomitant psychiatric conditions, the incidence of individual psychiatric events was low with lacosamide and carbamazepine-CR.
J o u r n a l P r e -p r o o f
Depression was the most common psychiatric TEAE during lacosamide treatment (4.7%),
whereas anxiety was the most common psychiatric TEAE during carbamazepine-CR treatment (6.5%), which is consistent with the different prevalence of these conditions at baseline (patients randomized to lacosamide had a higher prevalence of baseline depression and patients randomized to carbamazepine-CR had a higher prevalence of baseline anxiety).
There were no reports of psychotic disorder, epileptic psychosis, acute psychosis, or serious or severe psychiatric TEAEs during lacosamide treatment and only one patient discontinued due to a psychiatric TEAE (anxiety). One patient in the carbamazepine-CR group experienced a severe psychiatric TEAE (insomnia) and two patients discontinued due to a psychiatric TEAE (mental status change; suicidal ideation). No patients on carbamazepine-CR reported depression or depressed mood, which is not surprising given that carbamazepine is indicated in the EU for the prophylaxis of manic-depressive psychosis in patients unresponsive to lithium therapy (Novartis Pharmaceuticals UK Ltd, 2018). The incidences of psychiatric TEAEs (related to psychosis, depression, and suicide) were also low in a pooled analysis of adjunctive lacosamide trials (Biton et al., 2015) . Furthermore, adjunctive lacosamide was associated with a low incidence of predefined psychiatric-related TEAEs in a long-term noninterventional safety study in clinical practice (Steinhoff et al., 2016) .
One of the limitations of this analysis is that no specific instruments assessing depression and anxiety were applied. The data collected in this trial did not allow assessment of potential improvements in the comorbid psychiatric conditions, while worsening of a previous condition would have been captured as a TEAE. Previous studies of lacosamide in patients with epilepsy that used validated scales to assess depression and anxiety have shown generally favorable results. In a review of medical records, lacosamide was not associated with significant changes in depression and anxiety as assessed by Neurological Disorders Depression Inventory for Epilepsy (NDDI-E) and Generalized Anxiety Disorder 7-item scales (Moseley et al., 2015) . In a subgroup of patients with elevated initial NDDI-E scores, lacosamide had a beneficial effect on depressive symptoms (Moseley et al., 2015) . Two recent prospective studies assessed mood and quality of life before and after administration of adjunctive lacosamide (Lancman et al., 2016; Nakhutina et al., 2017) . One of these studies found that lacosamide has a low risk of adverse mood effects, while the results of the other study suggested that lacosamide may have a favorable impact on mood (Lancman et al., 2016; Nakhutina et al., 2017) . Two observational studies in clinical practice also suggested a positive effect of adjunctive lacosamide on depressive and anxiety symptoms and quality of life (Alfaro et al., 2019; Rocamora et al., 2018) . In patients with more severe anxiety, depression, and/or poorer quality of life at Baseline, lacosamide was associated with significant improvements (Alfaro et al., 2019; Rocamora et al., 2018) . These improvements J o u r n a l P r e -p r o o f could be a direct consequence of a reduction in seizure frequency or adverse events; however, one of these studies examined potential correlations and found that the effects of lacosamide on mood and anxiety were independent of seizure control (Rocamora et al., 2018) . In addition to the published data in patients with epilepsy, a recent study in patients with bipolar disorder (off-label use) suggested that lacosamide was effective in reducing psychopathology, mania, depression, and anxiety (Cuomo et al., 2018) . Together, these studies indicate that lacosamide may have beneficial psychotropic effects independent of antiseizure effects.
Kaplan-Meier estimates showed similar 6-and 12-month seizure freedom rates at the last evaluated dose in both treatment groups, indicating similar efficacy. However, a numerically higher proportion of patients on lacosamide than carbamazepine-CR completed 6 (67% vs 45%) and 12 months (50% vs 37%) of treatment without a seizure at the last evaluated dose.
This analysis of observed seizure freedom is considered a measure of effectiveness, as patients had to complete 6 or 12 months of treatment in addition to being seizure free, and potential reasons for discontinuation included lack of efficacy as well as adverse events. This numerical difference in effectiveness was likely related to the higher proportion of nonseizurerelated discontinuations among patients on carbamazepine-CR. The observed 6-month seizure freedom rates were lower among patients with concomitant psychiatric conditions than in the overall trial population, with a greater difference observed among patients on carbamazepine-CR (45% vs 70%) than lacosamide (67% vs 74%) (Baulac et al., 2017) . This may be explained by the lower proportion of patients with psychiatric conditions completing the trial in comparison with the overall trial population, or by the higher proportion of patients requiring a dose escalation to the highest permitted dose level (Baulac et al., 2017) . Patients with concomitant psychiatric conditions had a higher frequency of seizures in the 3 months before initiating AED treatment, which is strongly associated with poor seizure control (Mohanraj and Brodie, 2006) . In this subgroup of patients with psychiatric conditions, 37% of patients had six or more seizures in the 3 months before screening, in comparison with ~26% of patients overall (Baulac et al., 2017) . Furthermore, depression was the most common concomitant psychiatric condition in this subgroup (38%), and a history of depression before the onset of seizures has been linked to an increased risk of treatment-resistant epilepsy (Hitiris et al., 2007; Petrovski et al., 2010) .
Since patients with psychiatric comorbidities are likely to take additional concomitant medications (e.g., psychoanaleptics, psycholeptics), it may be preferable to select AEDs with a low potential for pharmacokinetic drug-drug interactions. This may help avoid the consequences of drug-drug interactions such as decreases in the efficacy of the concomitant drugs, increases of adverse events, and difficulties in managing appropriate dosages of the J o u r n a l P r e -p r o o f concomitant medications. Studies in healthy individuals and in patients with focal epilepsy have shown that lacosamide has a favorable pharmacokinetic profile and low potential for clinically relevant pharmacokinetic drug-drug interactions (Cawello et al., 2014) .
As this was a post hoc analysis with a limited number of patients, all outcomes were exploratory and the data should be interpreted with caution. In addition, all patients who reported at least one ongoing condition classified under the System Organ Class "Psychiatric
Disorders" according to MedDRA were included in the analysis, including patients with insomnia only (19 [15.1%]) and sleep disorder only (5 [4.0%]). As insomnia and sleep disorders may be caused by somatic issues, in addition to psychiatric disorders, it is possible that some patients did not have psychiatric conditions. While the MedDRA classification has its limitations, the analysis was performed using the System Organ Class "Psychiatric Disorders" in order to avoid bias in selecting specific terms of psychiatric conditions. The prevalence of psychiatric conditions among patients enrolled in the double-blind trial was relatively low (14.2%) compared with reports in the literature (Kanner, 2016b; Karouni et al., 2010) , which could at least partly be explained by the fact that patients with newly diagnosed epilepsy were enrolled and specific exclusion criteria were applied. In line with other regulatory monotherapy trials (Baulac et al., 2012; Jacobson et al., 2015; Rosenow et al., 2012; Sperling et al., 2015) , patients were not eligible to participate if they had medical or psychiatric conditions which, in the opinion of the investigator, could have jeopardized their health or compromised their ability to participate in the trial. In addition, monoamine oxidase inhibitors as well as medications known to interact with the trial medication were not allowed. Therefore, enrolled patients may have had relatively mild psychiatric conditions, and may not be fully representative of the wider population of patients with newly diagnosed epilepsy and psychiatric conditions. Despite its inherent limitations, this exploratory subgroup analysis reports data from a well-controlled, randomized, double-blind, active-comparator, monotherapy trial in patients with newly diagnosed epilepsy, and is particularly relevant given the high prevalence of psychiatric comorbidities in patients with epilepsy and the limited lacosamide data available for this patient population.
Conclusion
The results of this exploratory post-hoc analysis indicate that lacosamide monotherapy is efficacious and generally well tolerated in patients with newly diagnosed epilepsy and concomitant psychiatric conditions. These data, together with published data on the effect of adjunctive lacosamide on mood and quality of life, its favorable pharmacokinetic profile, and low potential for clinically relevant pharmacokinetic drug-drug interactions, suggest that J o u r n a l P r e -p r o o f lacosamide may be a suitable treatment option for initial monotherapy in patients with newly diagnosed epilepsy and concomitant psychiatric conditions. 
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